A machine learning approach to predict progression on active surveillance for prostate cancer.
A machine learning approach to predict progression on active surveillance for prostate cancer.
复制标题
DOI:
10.1016/j.urolonc.2021.08.007
复制
发表时间:
2022-04
期刊:
影响因子:
--
通讯作者:
Feldman AS
中科院分区:
文献类型:
--
作者:
Nayan M;Salari K;Bozzo A;Ganglberger W;Lu G;Carvalho F;Gusev A;Schneider A;Westover BM;Feldman AS
Robust prediction of progression on active surveillance (AS) for prostate cancer can allow for risk-adapted protocols. To date, models predicting progression on AS have invariably used traditional statistical approaches. We sought to evaluate whether a machine learning (ML) approach could improve prediction of progression on AS. We performed a retrospective cohort study of patients diagnosed with very-low or low-risk prostate cancer between 1997 and 2016 and managed with AS at our institution. In the training set, we trained a traditional logistic regression (T-LR) classifier, and alternate ML classifiers (support vector machine, random forest, a fully connected artificial neural network, and ML-LR) to predict grade-progression. We evaluated model performance in the test set. The primary performance metric was the F1 score. Our cohort included 790 patients. With a median follow-up of 6.29 years, 234 developed grade-progression. In descending order, the F1 scores were: support vector machine 0.586 (95% CI 0.579 – 0.591), ML-LR 0.522 (95% CI 0.513 – 0.526), artificial neural network 0.392 (95% CI 0.379 – 0.396), random forest 0.376 (95% CI 0.364 – 0.380), and T-LR 0.182 (95% CI 0.151 – 0.185). All alternate ML models had a significantly higher F1 score than the T-LR model (all p <0.001). In our study, ML methods significantly outperformed T-LR in predicting progression on AS for prostate cancer. While our specific models require further validation, we anticipate that a ML approach will help produce robust prediction models that will facilitate individualized risk-stratification in prostate cancer AS.
登录
查看更多内容
DOI:
10.1200/jco.2015.62.5764
发表时间:
2015-10-20
期刊:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子:
--
作者:
Tosoian JJ;Mamawala M;Epstein JI;Landis P;Wolf S;Trock BJ;Carter HB
通讯作者:
Carter HB
影响因子:
1.9
作者:
Morash, Chris;Tey, Rovena;Evans, Andrew
通讯作者:
Evans, Andrew
影响因子:
6.6
作者:
Sanda, Martin G.;Cadeddu, Jeffrey A.;Treadwell, Jonathan R.
通讯作者:
Treadwell, Jonathan R.
影响因子:
4.5
作者:
Pinsky, Paul F.;Miller, Eric;Andriole, Gerald
通讯作者:
Andriole, Gerald
影响因子:
4.3
作者:
Ross, Elsie Gyang;Shah, Nigam H.;Dalman, Ronald L.;Nead, Kevin T.;Cooke, John P.;Leeper, Nicholas J.
通讯作者:
Leeper, Nicholas J.